106 related articles for article (PubMed ID: 10396075)
1. Inhibition of pristane-induced peritoneal plasmacytoma formation.
Potter M; Kutkat L
Curr Top Microbiol Immunol; 1999; 246():351-61; discussion 361-2. PubMed ID: 10396075
[TBL] [Abstract][Full Text] [Related]
2. Indomethacin inhibition of pristane plasmacytomagenesis in genetically susceptible inbred mice.
Potter M
Adv Exp Med Biol; 1999; 469():151-6. PubMed ID: 10667324
[No Abstract] [Full Text] [Related]
3. Induction of B cell autoimmunity by pristane.
Richards HB; Satoh M; Shaheen VM; Yoshida H; Reeves WH
Curr Top Microbiol Immunol; 1999; 246():387-92; discussion 393. PubMed ID: 10396079
[No Abstract] [Full Text] [Related]
4. Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain.
Potter M; Wax J; Jones GM
Blood; 1997 Jul; 90(1):260-9. PubMed ID: 9207461
[TBL] [Abstract][Full Text] [Related]
5. Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.
McDonald AH; Degrassi A
Cell Immunol; 1993 Jan; 146(1):157-70. PubMed ID: 8425224
[TBL] [Abstract][Full Text] [Related]
6. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice.
Janz S; Shacter E
Cancer Biochem Biophys; 1995 Jun; 15(1):25-34. PubMed ID: 8536217
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of plasmacytoma development in BALB/c mice by indomethacin.
Potter M; Wax JS; Anderson AO; Nordan RP
J Exp Med; 1985 May; 161(5):996-1012. PubMed ID: 3989472
[TBL] [Abstract][Full Text] [Related]
8. Lipopolysaccharide and pristane-induced peritoneal exudate requirements for plasma tumor cell colony formation.
Platica M; Bojko C; Clincea R; Hollander V
J Natl Cancer Inst; 1982 Feb; 68(2):325-8. PubMed ID: 6950164
[TBL] [Abstract][Full Text] [Related]
9. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.
Avcu F; Ural AU; Yilmaz MI; Ozcan A; Ide T; Kurt B; Yalcin A
Eur J Haematol; 2005 Jun; 74(6):496-500. PubMed ID: 15876253
[TBL] [Abstract][Full Text] [Related]
10. Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice.
Felix K; Kelliher KA; Bornkamm GW; Janz S
Cancer Res; 1999 Aug; 59(15):3621-6. PubMed ID: 10446972
[TBL] [Abstract][Full Text] [Related]
11. In vitro mutagenicity of the plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane).
Felix K; Potter M; Bornkamm GW; Janz S
Cancer Lett; 1997 Feb; 113(1-2):71-6. PubMed ID: 9065804
[TBL] [Abstract][Full Text] [Related]
12. Perturbation of B cell genesis in the bone marrow of pristane-treated mice. Implications for plasmacytoma induction.
Rico-Vargas SA; Potter M; Osmond DG
J Immunol; 1995 Mar; 154(5):2082-91. PubMed ID: 7868885
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens.
Potter M; Wax JS
J Natl Cancer Inst; 1983 Aug; 71(2):391-5. PubMed ID: 6576197
[TBL] [Abstract][Full Text] [Related]
14. The fluidity of DOPC bilayers and membrane fractions prepared from murine plasmacytoma cells is unchanged after incorporation of pristane (2,6,10,14-tetramethylpentadecane) as assessed by fluorescence polarization analysis.
Janz S; Krumbiegel M; Gawrisch K
Cancer Biochem Biophys; 1992 Nov; 13(2):85-92. PubMed ID: 1343851
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice.
Chae BS; Shin TY; Kim DK; Eun JS; Leem JY; Yang JH
Arch Pharm Res; 2008 Apr; 31(4):503-10. PubMed ID: 18449509
[TBL] [Abstract][Full Text] [Related]
16. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.
Lattanzio G; Libert C; Aquilina M; Cappelletti M; Ciliberto G; Musiani P; Poli V
Am J Pathol; 1997 Sep; 151(3):689-96. PubMed ID: 9284817
[TBL] [Abstract][Full Text] [Related]
17. Plasmacytoma induction in specific pathogen-free (SPF) bcl-2 transgenic BALB/c mice.
Silva S; Klein G
Curr Top Microbiol Immunol; 1999; 246():379-85. PubMed ID: 10396078
[TBL] [Abstract][Full Text] [Related]
18. Experimental plasmacytoma in mice. I. Induction, morphological and biological characteristics.
Salwa J
Arch Immunol Ther Exp (Warsz); 1980; 28(1):167-72. PubMed ID: 7416920
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice.
Dedera DA; Urashima M; Chauhan D; LeBrun DP; Bronson RT; Anderson KC
Br J Haematol; 1996 Jul; 94(1):53-61. PubMed ID: 8757508
[TBL] [Abstract][Full Text] [Related]
20. Suppression of tumour-specific cytotoxic T-cell responses against the syngeneic BALB/c plasmacytoma ADJ-PC-5 by tumour-induced CD8+ regulatory T cells via IFN-gamma.
Pauels HG; Specht C; Becker C; Kölsch E
Scand J Immunol; 1996 Apr; 43(4):421-30. PubMed ID: 8668922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
